View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Delphine Brault ... (+6)
  • Delphine Brault
  • Emira Sagaama
  • Juan Ros-Padilla
  • Luis de Toledo Heras
  • Marc Lavaud
  • Nathan Mietlicki
Delphine Brault ... (+6)
  • Delphine Brault
  • Emira Sagaama
  • Juan Ros-Padilla
  • Luis de Toledo Heras
  • Marc Lavaud
  • Nathan Mietlicki
 PRESS RELEASE

Heineken Holding N.V. reports transactions under its current share bu...

Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 2 March 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026. From 23 February 2026 up to and including 27 February 2026 a total of 69,956 shares were repurchased on exchange at an average price of € 72.41. ...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in...

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine ...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la maladie liée aux IgG4Il s’agit de la troisième désignation mondiale de médicament orphelin pour le rilzabrutinib dans le traitement de la maladie liée aux IgG4, soulignant l’engagement de Sanofi dans la lutte contre les maladies rares à médiation...

 PRESS RELEASE

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU appr...

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can c...

 PRESS RELEASE

Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour...

Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent malgré un traitement   Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent malgré un traitement S’il est approuvé, Dupixent serait le premier médicament ciblé dans l’Union Européenne indiqué chez les enfants âgés de 2 à 11 ans atteints d’UCS insuffisamment contrôlées ...

 PRESS RELEASE

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, rec...

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness  Recommendation based on phase 2/3 study demonstrating up to 96 percent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sicknessThe therapy, given as a single dose of three tablets, c...

 PRESS RELEASE

Communiqué de presse: L’acoziborole Winthrop, développé par DNDi et Sa...

Communiqué de presse: L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil  La recommandation s’appuie sur une étude de phase 2/3, qui démontre jusqu’à 96 % de taux de réussite à 18 mois à des stades précoces et avancés de T.b. gambiense, la forme la plus courante de ...

Adecco Group AG: 1 director

A director at Adecco Group AG bought 4,000 shares at 20.900CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Heidelberg Materials AG: 1 director

A director at Heidelberg Materials AG bought 125 shares at 187.450EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

Heidelberg Materials AG: Strong results and acquisition of Maas Group'...

The results provide ample financial capacity to absorb the acquisition, regardless of the funding mix.

Chaima Ferrandon ... (+2)
  • Chaima Ferrandon
  • Sven Edelfelt
Chaima Ferrandon ... (+2)
  • Chaima Ferrandon
  • Sven Edelfelt
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch